{
    "clinical_study": {
        "@rank": "25067", 
        "arm_group": {
            "arm_group_label": "Non-Interventional Study"
        }, 
        "brief_summary": {
            "textblock": "This is a retrospective, non-interventional study which looks at the cohort of Renal Cell\n      Carcinoma patients in a real life clinical setting and analyses into factors why these\n      patients have been surviving for as long as 3-5 years unlike Clinical study where the\n      survival is around 2 years.\n\n      The factors which will be analysed include patient characteristics, dosage and adverse event\n      management and tries to correlate these factors with survival."
        }, 
        "brief_title": "A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Metastatic Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "A single cohort of 200 patients who are diagnosed with metastatic renal cell carcinoma prior\n      to 1st Jan 2012, and are seen by the medical oncologist at the centers involved with BIOGRID\n      and its affiliated registries. Patients will be identified from the first date of their\n      consultation with the medical oncologist and captured in the electronic database. Consent to\n      use datasets has already been obtained from participating research institutes and hospitals\n      IRB/Ethics Committees"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >18\n\n          -  Male or female\n\n          -  Metastatic renal cell cancer\n\n          -  First presentation with metastatic disease prior to 1st Jan 2012 since 2006, i.e.\n             between 1st Jan 2006 to 31st Dec 2011\n\n        Exclusion Criteria:\n\n          -  No referral to medical oncologist\n\n          -  No record available in electronic database"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All subjects who are diagnosed with metastatic renal cell carcinoma"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917214", 
            "org_study_id": "A6181210"
        }, 
        "intervention": {
            "arm_group_label": "Non-Interventional Study", 
            "description": "Sutent oral therapy", 
            "intervention_name": "Sutent: Observational Study", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Sunitinib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 18, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181210&StudyName=A%20Retrospective%20Real%20World%20Analysis%20Of%20Sutent%20In%20Patients%20With%20Metastatic%20Renal%20Cell%20Carcinoma%20In%20Community%20And%20Academic%20Centers%20To%20As"
        }, 
        "number_of_groups": "1", 
        "official_title": "Patterns of Care Among Australian Cohort of Patients With Advanced RCC Receiving Sutent", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: National Health and Medical Research Council", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Median time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (Weeks) = (first event date minus first dose date plus 1) divided by 7", 
            "measure": "Progression-Free Survival (PFS)", 
            "safety_issue": "Yes", 
            "time_frame": "4 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917214"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.", 
            "measure": "Overall Survival (OS)", 
            "safety_issue": "Yes", 
            "time_frame": "4 Months"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}